CNCEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (5 4月 2024 @ 05:00):

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases...

Stats
本日の出来高	10.73M
平均出来高	0.00
時価総額	401.95M
EPS	$0 ( 2023-08-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.64
ATR14	$0.231 (2.76%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-06	Van Heek Christi	Sell	25 651	Common Stock
2023-03-06	Van Heek Christi	Sell	16 400	Common Stock
2023-03-06	Van Heek Christi	Sell	25 000	Stock Option (Right to Buy)
2023-03-06	Van Heek Christi	Sell	10 000	Stock Option (Right to Buy)
2023-03-06	Van Heek Christi	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 4 463 235

ボリューム相関

長: 0.24 (neutral)

短: -0.57 (weak negative)

Signal:(66.67) Neutral

Concert Pharmaceuticals 相関

10 最も正の相関
NNOX	0.949
NERV	0.942
TYHT	0.942
MESA	0.94
RVNC	0.935
IDYA	0.932
PIRS	0.929
CELH	0.928
LIXT	0.928
MBINO	0.927

10 最も負の相関
TWKS	-0.963
FNWB	-0.958
HMST	-0.951
TCPC	-0.949
UPLD	-0.948
INFI	-0.942
EYE	-0.941
VNET	-0.94
SABRP	-0.939
TBNK	-0.938

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Concert Pharmaceuticals 相関 - 通貨/商品

0.81
( strong )

0.84
( strong )

-0.59
( weak negative )

0.62
( weak )

0.13
( neutral )

-0.41
( neutral )

Concert Pharmaceuticals 財務諸表

Annual	2021
収益:	$32 578.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00233

FY	2021
収益:	$32 578.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00233

FY	2020
収益:	$7.90M
総利益:	$7 902.00 (0.10 %)
EPS:	$-2.40

FY	2019
収益:	$1.08M
総利益:	$0.00 (0.00 %)
EPS:	$-3.29

Financial Reports:

No articles found.

Concert Pharmaceuticals

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.